Petersburg Post Home

The Petersburg Post

Omicron variant: NJ laboratory testing network ready?
- Searching for omicron: Is NJ's testing network ready for the new COVID variant? When COVID-19 variants were first detected in New Jersey in January, the state to identify these new mutations on a large scale, causing setbacks in determining their prevalence and tracking outbreaks. But over 11 months, laboratories have made significant improvements to speed up the process. Now, with the new omicron ...

The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more .
- Only 20 percent of ovarian cancers are found early, as there are often no symptoms – or they may mimic other common bladder, bowel, or gastrointestinal issues – and there is no screening test like those for breast and cervical cancer. By the time most women receive their diagnosis, the disease has advanced, which can include spread to intra-abdominal organs. Most patients then require surgery -; also called ...